Roberto Visentin

List of Publications by Year in Descending Order

40 papers	1,276 citations	18 h-index	35 g-index
41 ext. papers	1,500 ext. citations	6.4 avg, IF	4.21 L-index

#	Paper	IF	Citations
40	Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon-like peptide-1/glucagon receptor agonist SAR425899 in comparison with liraglutide. *Diabetes, Obesity and Metabolism*, **2021**, 23, 1795-1805	6.7	8
39	Determinants of hepatic insulin clearance - Results from a Mendelian Randomization study. *Metabolism: Clinical and Experimental*, **2021**, 119, 154776	12.7	1
38	A Novel Method for Generation of In Silico Subjects with Type 2 Diabetes. *Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual International Conference*, **2021**, 2021, 1380-1383	0.9	
37	The Padova Type 2 Diabetes Simulator from Triple-Tracer Single-Meal Studies: Trials Also Possible in Rare but Not-So-Rare Individuals. *Diabetes Technology and Therapeutics*, **2020**, 22, 892-903	8.1	8
36	Head-to-Head Comparison of Insulin Glargine 300 U/mL and Insulin Degludec 100 U/mL in Type 1 Diabetes. *Diabetes Technology and Therapeutics*, **2020**, 22, 553-561	8.1	9
35	691-P: Exercise Effect on Endogenous Glucose Production in Type 1 Diabetes: A Modeling Analysis. *Diabetes*, **2020**, 69, 691-P	0.9	0
34	1744-P: Hepatic and Disposal Insulin Sensitivity with Single Tracer Method: Use of Naturally Abundant 13C-Polysaccharide. *Diabetes*, **2020**, 69, 1744-P	0.9	
33	1856-P: Hepatic Insulin Clearance Is Not Driven by Liver Fat but by Systemic Inflammation: A Mendelian Randomization Study. *Diabetes*, **2020**, 69, 1856-P	0.9	1
32	Dual glucagon-like peptide-1 receptor/glucagon receptor agonist SAR425899 improves beta-cell function in type 2 diabetes. *Diabetes, Obesity and Metabolism*, **2020**, 22, 640-647	6.7	14
31	In Silico Cloning of Target Type 2 Diabetes Population for Treatments Development and Decision Support. *Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual International Conference*, **2020**, 2020, 5111-5114	0.9	1
30	Modeling Subcutaneous Absorption of Long-Acting Insulin Glargine in Type 1 Diabetes. *IEEE Transactions on Biomedical Engineering*, **2020**, 67, 624-631	5	7
29	Mechanisms of hyperinsulinaemia in apparently healthy non-obese young adults: role of insulin secretion, clearance and action and associations with plasma amino acids. *Diabetologia*, **2019**, 62, 2310-2324	10.2	7
28	Physiological models for artificial pancreas development **2019**, 123-152		2
27	Incorporating Long-Acting Insulin Glargine Into the UVA/Padova Type 1 Diabetes Simulator for In Silico Testing of MDI Therapies. *IEEE Transactions on Biomedical Engineering*, **2019**, 66, 2889-2896	5	11
26	The UVA/Padova Type 1 Diabetes Simulator Goes From Single Meal to Single Day. *Journal of Diabetes Science and Technology*, **2018**, 12, 273-281	4.1	86
25	Toward a Run-to-Run Adaptive Artificial Pancreas: In Silico Results. *IEEE Transactions on Biomedical Engineering*, **2018**, 65, 479-488	5	55
24	Parental evaluation of a telemonitoring service for children with Type 1 Diabetes. *Journal of Telemedicine and Telecare*, **2018**, 24, 230-237	6.8	11

23	Effects of the Novel Dual GLP-1R/GCGR Agonist SAR425899 on Postprandial Glucose Metabolism in Overweight/Obese Subjects with Type 2 Diabetes. *Diabetes*, **2018**, 67, 72-OR	0.9	4
22	A Model of Acetaminophen Pharmacokinetics and its Effect on Continuous Glucose Monitoring Sensor Measurements. *Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual International Conference*,	0.9	1
21	Long-acting Insulin in Diabetes Therapy: In Silico Clinical Trials with the UVA/Padova Type 1 Diabetes Simulator. *Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual International Conference*, **2018**, 2018, 4905-4908	0.9	1
20	Randomized Controlled Trial of a MUFA or Fiber-Rich Diet on Hepatic Fat in Prediabetes. *Journal of Clinical Endocrinology and Metabolism*, **2017**, 102, 1765-1774	5.6	41
19	Accuracy of a CGM Sensor in Pediatric Subjects With Type 1 Diabetes. Comparison of Three Insertion Sites: Arm, Abdomen, and Gluteus. *Journal of Diabetes Science and Technology*, **2017**, 11, 1147-1154	4.1	23
18	Individually Adaptive Artificial Pancreas in Subjects with Type 1 Diabetes: A One-Month Proof-of-Concept Trial in Free-Living Conditions. *Diabetes Technology and Therapeutics*, **2017**, 19, 560-571	8.1	40
17	Overnight Closed-Loop Control Improves Glycemic Control in a Multicenter Study of Adults With Type 1 Diabetes. *Journal of Clinical Endocrinology and Metabolism*, **2017**, 102, 3674-3682	5.6	15
16	A Hybrid Clustering Prediction for Type 1 Diabetes Aid: Towards Decision Support Systems Based upon Scenario Profile Analysis **2017**,		4
15	Personalized blood glucose prediction: A hybrid approach using grammatical evolution and physiological models. *PLoS ONE*, **2017**, 12, e0187754	3.7	39
14	Evaluating the Experience of Children With Type 1 Diabetes and Their Parents Taking Part in an Artificial Pancreas Clinical Trial Over Multiple Days in a Diabetes Camp Setting. *Diabetes Care*, **2016**, 39, 2158-2164	14.6	23
13	Improving Efficacy of Inhaled Technosphere Insulin (Afrezza) by Postmeal Dosing: In-silico Clinical Trial with the University of Virginia/Padova Type 1 Diabetes Simulator. *Diabetes Technology and Therapeutics*, **2016**, 18, 574-85	8.1	24
12	Randomized Summer Camp Crossover Trial in 5- to 9-Year-Old Children: Outpatient Wearable Artificial Pancreas Is Feasible and Safe. *Diabetes Care*, **2016**, 39, 1180-5	14.6	68
11	Day-and-Night Closed-Loop Glucose Control in Patients With Type 1 Diabetes Under Free-Living Conditions: Results of a Single-Arm 1-Month Experience Compared With a Previously Reported Feasibility Study of Evening and Night at Home. *Diabetes Care*, **2016**, 39, 1151-60	14.6	88
10	One-Day Bayesian Cloning of Type 1 Diabetes Subjects: Toward a Single-Day UVA/Padova Type 1 Diabetes Simulator. *IEEE Transactions on Biomedical Engineering*, **2016**, 63, 2416-2424	5	44
9	Multinight "bedside" closed-loop control for patients with type 1 diabetes. *Diabetes Technology and Therapeutics*, **2015**, 17, 203-9	8.1	47
8	2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial. *Lancet Diabetes and Endocrinology,the*, **2015**, 3, 939-47	18.1	174
7	Multicenter outpatient dinner/overnight reduction of hypoglycemia and increased time of glucose in target with a wearable artificial pancreas using modular model predictive control in adults with type 1 diabetes. *Diabetes, Obesity and Metabolism*, **2015**, 17, 468-76	6.7	78
6	Hepatic insulin sensitivity in healthy and prediabetic subjects: from a dual- to a single-tracer oral minimal model. *American Journal of Physiology - Endocrinology and Metabolism*, **2015**, 309, E161-7	6	12

5	Incorporation of inhaled insulin into the FDA accepted University of Virginia/Padova Type 1 Diabetes Simulator. *Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual International Conference*, **2015**, 2015, 3250-3	0.9	1
4	Circadian variability of insulin sensitivity: physiological input for in silico artificial pancreas. *Diabetes Technology and Therapeutics*, **2015**, 17, 1-7	8.1	57
3	First use of model predictive control in outpatient wearable artificial pancreas. *Diabetes Care*, **2014**, 37, 1212-5	14.6	77
2	The university of Virginia/Padova type 1 diabetes simulator matches the glucose traces of a clinical trial. *Diabetes Technology and Therapeutics*, **2014**, 16, 428-34	8.1	51
1	Feasibility of outpatient fully integrated closed-loop control: first studies of wearable artificial pancreas. *Diabetes Care*, **2013**, 36, 1851-8	14.6	143